compound 37 [PMID: 29193967]   Click here for help

GtoPdb Ligand ID: 9797

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 37 [PMID: 29193967] is a potent, orally bioavailable PLA2-G7 (Lp-PLA2) inhibitor. Structurally it is has a novel sulfonamide scaffold, and is a candidate for further optimisation. Compounds of different chemotypes are being explored as tools to examine the pharmacological modulation of PLA2-G7 as a target for clinical intervention- see also darapladib (failed Phase 3 trial in coronary heart disease), rilapladib (completed Phase 2 for Alzheimer's disease) and (S)-23 [PMID: 27933945] (tool compound).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 113.59
Molecular weight 467.03
XLogP 4.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1cc(ccc1Oc1ccc(c(c1)C(F)(F)F)Cl)NS(=O)(=O)c1ccc(cc1)N
Isomeric SMILES N#Cc1cc(ccc1Oc1ccc(c(c1)C(F)(F)F)Cl)NS(=O)(=O)c1ccc(cc1)N
InChI InChI=1S/C20H13ClF3N3O3S/c21-18-7-4-15(10-17(18)20(22,23)24)30-19-8-3-14(9-12(19)11-25)27-31(28,29)16-5-1-13(26)2-6-16/h1-10,27H,26H2
Immunopharmacology Comments
PLA2-G7 inhibitors exhibit anti-inflammatory properties that may be relevant in conditions other than atherosclerosis that also have an inflammatory component [2-3].